Results 61 to 70 of about 108,588 (261)

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report

SAGE Open Medical Case Reports
Despite advancements in the treatment of diffuse large B-cell lymphoma, including CAR T-cell therapy, TP53 mutations remain a significant negative prognostic factor in patients with relapsed/refractory diffuse large B-cell lymphoma.
Ziyi Cai, Dongmei Zou, Qiang Ma, Wanling Sun, Yixian Guo   +4 more
doaj   +1 more source

Head and Neck Lymphoma in an Iranian Population [PDF]

Iranian Journal of Otorhinolaryngology, 2017
Introduction: This study is aimed to assess the prevalence and characteristics of head and neck lymphoma in a defined group of an Iranian population.   Materials and Methods: In this retrospective study, 126,450 biopsy reports from two referral Pathology
Nafiseh Shamloo, Alireza Ghannadan, Mahsa Jafari, Samane Ahmadi, Hamed Mortazavi, Maryam Baharvand   +5 more
doaj   +1 more source

Treatment of Diffuse Large B-Cell Lymphoma

Journal of Clinical and Experimental Hematopathology, 2016
Diffuse large B-cell lymphoma (DLBCL) comprises a heterogeneous group with pathophysiological, genetic and clinical features. Many patients can be cured with R-CHOP therapy, which is the current standard regimen. Despite recent progress in improving patient survival, the 40% survival of DLBCL patients remains poor.
openaire   +3 more sources

Fibrin‐associated diffuse large B‐cell lymphoma [PDF]

British Journal of Haematology, 2019
n ...
Zanelli, Magda, Zizzo, Maurizio, De Marco, Loredana, Bisagni, Alessandra, Ascani, Stefano   +4 more
openaire   +3 more sources

De Novo Designed Minibinders Targeting the GDF15–GFRAL Axis Reverse Cancer Cachexia and Restore Anti‐Tumor Immunity

Advanced Science, EarlyView.
Tumor‐derived GDF15 drives cancer cachexia and suppresses antitumor immunity. Here, de novo designed minibinders targeting the GDF15–GFRAL interface achieve picomolar affinity and potent pathway blockade. The minibinders alleviate cachexia, restore CD8+ T‐cell infiltration, enhance anti–PD‐1 responsiveness, and provide survival benefits across tumor ...
Haitao Wang, Tianzhen Hua, Meiling Wang, Bingbing Meng, Yue Zhang, Chengxu Jiang, Yunhe Gao, Hongqi Yang, Jian Bo   +8 more
wiley   +1 more source

Single‐Cell Profiling Identifies SLC2A5‐Mediated Fructose Metabolism as a Vulnerability in Primary CNS Lymphoma

Advanced Science, EarlyView.
Glucose deprivation in the primary CNS lymphoma (PCNSL) tumor microenvironment drives SLC2A5 (encoding GLUT5)‐dependent fructose metabolism in tumor cells, while hypoxia induces HIF‐mediated SLC2A5 expression in tumor‐supportive macrophages, revealing SLC2A5‐driven fructose utilization as a shared and targetable metabolic vulnerability across malignant
Qiaoli Wu, Qianru Zhang, Wenqiang Yan, Lu Sun, Yiran Cui, Bolin Liu, Guoqing Han, Feng Zhang, Ke Pu, Mingchao Zhang, Xiaobing Zhang, Qingguo Li, Gang An, Yuxuan Liu   +13 more
wiley   +1 more source

The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection

Haematologica, 2015
Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma. Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB ...
Luca Arcaini, Davide Rossi, Marco Lucioni, Marta Nicola, Alessio Bruscaggin, Valeria Fiaccadori, Roberta Riboni, Antonio Ramponi, Virginia V. Ferretti, Stefania Cresta, Gloria Margiotta Casaluci, Maurizio Bonfichi, Manuel Gotti, Michele Merli, Aldo Maffi, Mariarosa Arra, Marzia Varettoni, Sara Rattotti, Lucia Morello, Maria Luisa Guerrera, Roberta Sciarra, Gianluca Gaidano, Mario Cazzola, Marco Paulli   +23 more
doaj   +1 more source

The Genetic Landscape of Diffuse Large B-Cell Lymphoma [PDF]

Seminars in Hematology, 2015
Diffuse large B-cell lymphoma (DLBCL), the most common lymphoid malignancy in the western world, is an aggressive disease that remains incurable in approximately 30% of patients. Over the past decade, the rapid expansion of sequencing technologies allowing the genome-wide assessment of genomic and transcriptional changes has revolutionized our ...
PASQUALUCCI, Laura, Dalla Favera, Riccardo   +1 more
openaire   +2 more sources

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

Advanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao, Zhenyuan Jia, Xiao‐Qin Mu, Ruilin Wang, Jianli Ma, Qingyuan Zhang, Yuwei Deng   +6 more
wiley   +1 more source

Cancer‐Associated BCL‐2 Mutants Reveal Mechanisms Towards Venetoclax Resistance

Advanced Science, EarlyView.
Venetoclax (VEN) resistance in chronic lymphocytic leukemia arises from diverse BCL2 mutations. We map mechanisms contributing to VEN resistance across common BCL‐2 variants. G101V and D103Y reduce drug binding and increase sequestration of pro‐apoptotic proteins. V156D blocks VEN allosterically.
Jonas Aufdermauer, Ian de Ridder, Mahjoobeh Ehsani, Marasim Khan, Justin Kale, Lukas P. Frenzel, David Andrews, Spyridoula Karamanou, Ana J. Garcia‐Saez, Geert Bultynck   +9 more
wiley   +1 more source